Skip to content
GLP-1 Decoder

Semaglutide: Uses, How It Works, Side Effects, Cost

Semaglutide is the active ingredient in Ozempic, Wegovy and Rybelsus, all from Novo Nordisk. The first Semaglutide brand, Ozempic, was FDA approved in 2017. The lowest self-pay price is $149 per month for Wegovy.

Brands
Ozempic, Wegovy and Rybelsus
Manufacturer
Novo Nordisk
First brand approved
2017, Ozempic
Best trial weight loss
14.9% (STEP 1)
Lowest self-pay
$149 per month, Wegovy
FDA shortage
Resolved February 21, 2025
Semaglutide: a GLP-1 pen injector

Wegovy: key facts

Time it remains in the body
100%50%25%0%07 d14 d21 d28 d35 d50%25%12.5%time after the dose

Its half-life is about 1 week: after 7 d, half is gone, and about 3% remains after five half-lives (35 d).

Weight loss in its main trial
Wegovy (STEP 1)14.9%Placebo2.4%

STEP 1 showed 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.

Prices over time
202520262027$1,349.02$0List priceSelf-pay

Monthly prices in US dollars include list prices and self-pay offers, each taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Semaglutide brands compared

Each brand has the same ingredient, but its own label, uses and price.

These are all the Semaglutide brands sold in the US
BrandHow it is takenApproved forFirst approvedList priceSelf-pay from
Ozempicweekly injectionType 2 diabetes, heart risk, and kidney disease with type 2 diabetes2017$1,027.51 per pen$199 per month
Wegovyweekly injection or daily tabletWeight loss, heart risk and MASH liver disease2021$1,349.02 per month$149 per month
Rybelsusdaily tabletType 2 diabetes and heart risk2019$1,027.51 per 30 tabletsNot listed
Sources (7)

Novo Nordisk prices: 1 2, TrumpRx 1 2, FDA label 1 2 3.

What the Semaglutide trials showed

Main Semaglutide trial Results
TrialWho took partLengthGroupAverage weight lossPlacebo
STEP 1Adults with obesity or overweight, without diabetes68 weeksSemaglutide 2.4 mg weekly14.9%2.4%
OASIS 4Adults with obesity or overweight, without diabetes64 weeksWegovy pill 25 mg daily13.6%2.4%
STEP 2Adults with obesity or overweight who also have type 2 diabetes68 weeksSemaglutide 2.4 mg weekly9.6%3.4%
STEP-HFpEFAdults with obesity who also have heart failure whose ejection fraction is preserved52 weeksSemaglutide 2.4 mg weekly13.3%2.6%
Sources (10)

PubMed sources: 1 2 3 4 5 6 7 8 9, plus the FDA label on DailyMed.

Semaglutide side effects

The labels covered different people and doses, so compare values within the same column first.

Semaglutide side effects for each brand at the top dose on its label
Side effectOzempicWegovyRybelsus
Nausea20.3%44%20%
Diarrhea8.8%30%10%
Vomiting9.2%24%8%
Constipation5%24%6%
Abdominal pain7.3%20%11%
HeadacheNot listed14%Not listed
Decreased appetiteNot listedNot listed9%

Sources: FDA label (DailyMed) 1 2 3.

These warnings come from the FDA label (DailyMed).

Generic and compounded Semaglutide

The injection shortage ended on February 21, 2025. Older Rybelsus tablets are being discontinued.

Sources: FDA 1 2.

Every Semaglutide page

Semaglutide en espaƱol